Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Kyndryl Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Kyndryl Holdings Inc trades at $12.36 (market cap $2.64B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 15.1× Kyndryl Holdings Inc's market cap. Which is the better fit depends on your goals.
| ALNY | KD | |
|---|---|---|
Market Cap | $39.89B | $2.64B |
Sector | Health | Technology |
52-Week High | $491.22 | $39.78 |
52-Week Low | $278.09 | $10.59 |
Enterprise Value | $38.15B | $4.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Kyndryl Holdings (KD) trades at $11.97, down 0.83% on the day, with technical indicators signaling a bearish trend. The company reported revenue of $15.06B in 2025, achieving a net income of $252M after three years of losses. Recent news includes leadership changes and legal investigations, while analyst consensus is mixed with a $14.33 price target. Cash flow improved to a net positive $236M in 2025, though debt levels remain elevated.
The outlook is cautious; profitability improvements and strategic partnerships offer potential upside, but legal risks and recent earnings misses pose significant challenges. Investors should weigh the low P/E of 14.08 against ongoing operational and sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
